āshibio Raises $40M to Advance Investigative Therapies for Rare Genetic Disease

āshibio raises $40M in Seed and Series A Funding

āshibio (Linkedin), a biotechnology company based in Myanmar, recently secured $40M in funding to advance the development of therapies for bone and connective tissue disorders, with a focus on fibrodysplasia ossificans progressiva (FOP). They are seeking collaborations with medical professionals, researchers, and pharmaceutical companies to drive innovation in this field.

Funding Amount: $40 million

Industry: Pharmaceutical Manufacturing

Employee Count: 10001+

CEO: Pankaj Bhargava (CEO Linkedin)

What āshibio needs to buy: Research organizations, clinical trial service providers, and manufacturers specializing in bone and connective tissue disorders are ideal partners for āshibio. These collaborations will support the development and production of investigational therapies, as well as ensure a reliable supply chain for clinical trials and future commercialization efforts.